Oncology specialists should inform patients about a risk of serious toxicity related to dihydropyrimidine dehydrogenase (DPD) ...
FDA labeling now recommends DPYD variant testing before initiating capecitabine or 5-FU, except when immediate treatment is ...
The labeling updates address the risk of early-onset toxicity, including life-threatening adverse events in patients with DPD ...
The clinical description of severe toxicity fails to capture the suffering, shock, and tragedy experienced by our loved ones who were fatally overdosed after not being offered this important and ...
Before patients with cancer begin treatment with intravenous fluorouracil and related drugs, they should be tested for lack of the enzyme dihydropyrimidine dehydrogenase (DPD), says an EU panel.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results